Sumanta K. Pal Discusses Strides Made in Kidney Cancer Care
Sumanta K. Pal, MD, City of Hope Cancer Center, discusses the great strides in kidney cancer care that have been made in the past decade.
Sumanta K. Pal, MD, City of Hope Cancer Center, discusses the great strides in kidney cancer care that have been made in the past decade.
Throughout the past 10 years, treatment for kidney cancer has continued to evolve, with at least seven new targeted therapies approved, making the survival rate triple. Also, Pal notes that doctors are bringing back immune-based treatment in more targeted and specific ways, which he believes will further improve survival rates for the disease.
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes vs Chemo in Urothelial Cancer
April 20th 2024Patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin plus pembrolizumab experienced a reduction in the risk for disease progression or death vs chemotherapy.
Maintenance Avelumab Has Similar Efficacy in Real World for Urothelial Cancer
March 5th 2024Patients with metastatic urothelial cancer treated with frontline maintenance therapy with avelumab following platinum-based chemotherapy in the real-world setting had similar outcomes as observed in the JAVELIN Bladder 100 trial.
Key Advances in Cancer Survivorship Toxicity Management
July 15th 2022In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.
